TIMP1 and keloid: Here, we observed that sorafenib not only reduced the expression of fibrotic ECM components (Figs. 4a, b and 8) but also modulated the MMPs/TIMP-1 ratio to potentially promote the degradation of ECM proteins (Fig. 4c), thereby promising a reverse of the established fibrosis in keloids.